Does The Hype Around MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) Growth Justify Its August Share Price?

MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) is a stock well-positioned for future growth, but many investors are wondering whether its last closing price of €94.58 is based on unrealistic expectations. Let’s look into this by assessing MRK’s expected growth over the next few years.

View our latest analysis for MERCK Kommanditgesellschaft auf Aktien

Has the MRK train slowed down?

Analysts are predicting good growth prospects for MERCK Kommanditgesellschaft auf Aktien over the next couple of years. The consensus forecast from 22 analysts is bullish with earnings per share estimated to surge from current levels of €2.574 to €4.906 over the next three years. This indicates an estimated earnings growth rate of 15% per year, on average, which illustrates an optimistic outlook in the near term.

Is MRK’s share price justifiable by its earnings growth?

MRK is trading at quite a high price-to-earnings (PE) ratio of 36.75x. This tells us that MERCK Kommanditgesellschaft auf Aktien is overvalued compared to the DE market average ratio of 19.19x , and overvalued based on current earnings compared to the Pharmaceuticals industry average of 26.9x .

DB:MRK Price Estimation Relative to Market, August 12th 2019
DB:MRK Price Estimation Relative to Market, August 12th 2019

We already know that MRK appears to be overvalued when compared to its industry average. However, since MERCK Kommanditgesellschaft auf Aktien is a high-growth stock, we must also account for its earnings growth by using calculation called the PEG ratio. A PE ratio of 36.75x and expected year-on-year earnings growth of 15% give MERCK Kommanditgesellschaft auf Aktien a quite high PEG ratio of 2.47x. Based on this growth, MERCK Kommanditgesellschaft auf Aktien’s stock can be considered overvalued , based on its fundamentals.

What this means for you:

MRK’s current overvaluation could signal a potential selling opportunity to reduce your exposure to the stock, or it you’re a potential investor, now may not be the right time to buy. However, basing your investment decision off one metric alone is certainly not sufficient. There are many things I have not taken into account in this article and the PEG ratio is very one-dimensional. If you have not done so already, I highly recommend you to complete your research by taking a look at the following:

  1. Financial Health: Are MRK’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  2. Past Track Record: Has MRK been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of MRK’s historicals for more clarity.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.